Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to
recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic …

Background Docetaxel (DTX) resistance reduces therapeutic efficacy in prostate cancer
(PCa). Accumulating reports support the role of phytochemicals in the reversal of DTX …

Prostate cancer (PCa) is the second leading cause of cancer-related death among men in
western countries. Evidence has indicated the significant role of the androgen receptor (AR) …

METTL3, a primary methyltransferase catalyzing the RNA N6‐methyladenosine (m6A)
modification, has been identified as an oncogene in several cancer types and thus …

METTL3 has emerged as a promising therapeutic target in cancer treatment, although its
oncogenic functions in melanoma development and potential for therapeutic targeting drug …

Abstract Background Circular RNAs (circRNAs) have been shown to be involved in
tumorigenesis and progression. However, the role of circGLIS3 (hsa_circ_0002874) in …

The RNA N 6-methyladenosine (m6A) regulator METTL3 is an important regulatory gene in
various progressive processes of prostate cancer (PCa). METTL3 inhibitors have been …

Studies have shown that androgens can alleviate the symptoms of T2 asthma and are
inversely correlated with the severity of allergic asthma. METTL3, a crucial component of …

Abstract N6-methyladenosine (m6A) methylation is a dynamic and reversible procession of
epigenetic modifications. It is increasingly recognized that m6A modification has been …

RNA methylation is a dynamic and ubiquitous post-transcriptional modification that plays a
pivotal role in regulating gene expression in various conditions like cancer, neurological …